Next Article in Journal
Disseminated Mycobacterium avium complex in an Adolescent with Perinatally-Acquired HIV Infection
Previous Article in Journal
Epidemiology and Clinical Complication Patterns of Influenza A (H1N1 Virus) in Northern Saudi Arabia
 
 
Infectious Disease Reports is published by MDPI from Volume 12 Issue 3 (2020). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Antiretroviral Therapy Containing Raltegravir to Prevent Mother-to-Child Transmission of HIV in Infected Pregnant Women

by
Diego M. Cecchini
*,
Marina G. Martinez
,
Laura M. Morganti
and
Claudia G. Rodriguez
Hospital General de Agudos “Cosme Argerich”, Buenos Aires, Argentina
*
Author to whom correspondence should be addressed.
Infect. Dis. Rep. 2017, 9(2), 7017; https://doi.org/10.4081/idr.2017.7017
Submission received: 11 November 2016 / Revised: 13 March 2017 / Accepted: 17 March 2017 / Published: 14 June 2017

Abstract

We conducted a retrospective study in a general hospital in Buenos Aires, Argentina (2009-2015) aimed at evaluating outcomes in HIV-infected pregnant women (HIPW), who were prescribed raltegravir (RAL)- containing antiretroviral therapy (ART). A total of 239 HIPW were enrolled in our study; among them 31 received RAL (12.9%) at different clinical stages: i) intensification (INS): addition of RAL to current ART because of detectable antepartum viral load, 13 (41.9%); ii) late presenter (LP): standard ART + RAL as fourth drug, 15 (48.4%); iii) treatment of resistant-HIV: 3 (9.7%). Median gestational age at RAL initiation was 34 weeks and median exposure was 30 days. In INS-group, median viral load (VL) decrease was 1.48 log10. In LPgroup, median VL decline was 2.15 log10. No clinical adverse events or maternal intolerance attributable to RAL were observed. Elective cesarean section was done in 51.7%; mild elevation of transaminases was observed in 35% of neonates. No vertical transmission was documented.
Keywords: Pregnancy; HIV; raltegravir; antiretroviral therapy Pregnancy; HIV; raltegravir; antiretroviral therapy

Share and Cite

MDPI and ACS Style

Cecchini, D.M.; Martinez, M.G.; Morganti, L.M.; Rodriguez, C.G. Antiretroviral Therapy Containing Raltegravir to Prevent Mother-to-Child Transmission of HIV in Infected Pregnant Women. Infect. Dis. Rep. 2017, 9, 7017. https://doi.org/10.4081/idr.2017.7017

AMA Style

Cecchini DM, Martinez MG, Morganti LM, Rodriguez CG. Antiretroviral Therapy Containing Raltegravir to Prevent Mother-to-Child Transmission of HIV in Infected Pregnant Women. Infectious Disease Reports. 2017; 9(2):7017. https://doi.org/10.4081/idr.2017.7017

Chicago/Turabian Style

Cecchini, Diego M., Marina G. Martinez, Laura M. Morganti, and Claudia G. Rodriguez. 2017. "Antiretroviral Therapy Containing Raltegravir to Prevent Mother-to-Child Transmission of HIV in Infected Pregnant Women" Infectious Disease Reports 9, no. 2: 7017. https://doi.org/10.4081/idr.2017.7017

Article Metrics

Back to TopTop